Rate My Professor Dashiell Gantner

Dr Dashiell Gantner, BSc, MBBS, PhD, FRACP, FCICM, MAICD, is a Senior Staff Specialist in Intensive Care Medicine at The Alfred Hospital and an Adjunct Senior Lecturer in Acute & Critical Care in the Department of Epidemiology and Public Health, School of Public Health and Preventive Medicine at Monash University. He has served as Consultant Intensivist at Alfred Hospital since March 2016, Clinical Lead for ICU Burns, Extra-Corporeal Membrane Oxygenation (ECMO) specialist, and Medical Donation Specialist coordinating organ donation and transplantation services for Alfred Health. Gantner also acts as a PhD Supervisor at the University of Melbourne and has been an advisor to the Australian Clinical Trials Alliance since 2019.

Gantner's PhD, undertaken with the Australian and New Zealand Intensive Care Research Centre, addressed the implementation of evidence in clinical practice for neurotrauma management. His research interests include neurocritical care, transfusion medicine, fluid management, resuscitation, and evidence implementation in clinical practice. He has over 50 peer-reviewed publications, with his Google Scholar profile recording 8,687 total citations, an h-index of 34, and i10-index of 56. Key publications include 'Development of a Quality Indicator Set for the Optimal Acute Management of Moderate to Severe Traumatic Brain Injury in the Australian Context' (Neurocritical Care, 2025), 'Hyperoxia and unfavourable outcome in patients with non-traumatic subarachnoid haemorrhage: A systematic review and meta-analysis' (Journal of Clinical Neuroscience, 2025), 'One-year employment outcome prediction after traumatic brain injury: a CENTER-TBI study' (Disability and Health Journal, 2025), and 'The impact of a tailored nutrition intervention delivered for the duration of hospitalisation on daily energy delivery for patients with critical illness (INTENT): a phase II randomised controlled trial' (Critical Care, 2025). As Chief Investigator, he has led the Pre-hospital Antifibrinolytics for Traumatic Coagulopathy and Haemorrhage (PATCH) Study (2013-2018), PATCH2 Study (2019-2022), and EPO-TRAUMA trial (2019-2026), advancing critical care practices internationally.